1. 207499/039 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease (207499/039) gsk-clinicalstudyregister.com/study/207499/039#rs
2. Cilomilast (Ariflo) a potent selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: results of a 6 month trial;Edelson;American Journal of Respiratory and Critical Care Medicine,2001
3. Cilomilast (Ariflo) improves health status in patients with COPD: results of a 6-month trial;Edelson;American Journal of Respiratory and Critical Care Medicine,2001
4. Cilomilast for COPD: results of a 6-month, placebo controlled study of a potent, selective inhibitor of phosphodiesterase 4;Rennard;Chest,2006
5. 207499/042 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease www.gsk-clinicalstudyregister.com/study/207499/039?search=study&search_terms=cilomilast&search=Search#rs